Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases

Christine Beeton, Michael W. Pennington, Heike Wulff, Satendra Singh, Daniel Nugent, George Crossley, Ilya Khaytin, Peter Calabresi, Chao Yin Chen, George A. Gutman, K. George Chandy

Research output: Contribution to journalArticle

Abstract

The voltage-gated Kv1.3 K+ channel is a novel target for immunomodulation of autoreactive effector memory T (TEM) cells that play a major role in the pathogenesis of autoimmune diseases. We describe the characterization of the novel peptide ShK(L5) that contains L-phosphotyrosine linked via a nine-atom hydrophilic linker to the N terminus of the ShK peptide from the sea anemone Stichodactyla helianthus. ShK(L5) is a highly specific Kv1.3 blocker that exhibits 100-fold selectivity for Kv1.3 (Kd = 69 pM) over Kv1.1 and greater than 250-fold selectivity over all other channels tested. ShK(L5) suppresses the proliferation of human and rat TEM cells and inhibits interleukin-2 production at picomolar concentrations. Naive and central memory human T cells are initially 60-fold less sensitive than TEM cells to ShK(L5) and then become resistant to the peptide during activation by up-regulating the calcium-activated KCa3.1 channel. ShK(L5) does not exhibit in vitro cytotoxicity on mammalian cell lines and is negative in the Ames test. It is stable in plasma and when administered once daily by subcutaneous injection (10 μg/kg) attains "steady state" blood levels of ≃300 pM. This regimen does not cause cardiac toxicity assessed by continuous EKG monitoring and does not alter clinical chemistry and hematological parameters after 2-week therapy. ShK(L5) prevents and treats experimental autoimmune encephalomyelitis and suppresses delayed type hypersensitivity in rats. ShK(L5) might prove useful for therapy of autoimmune disorders.

Original languageEnglish (US)
Pages (from-to)1369-1381
Number of pages13
JournalMolecular Pharmacology
Volume67
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Autoimmune Diseases
T-Lymphocytes
Peptides
Sea Anemones
Voltage-Gated Potassium Channels
Clinical Chemistry
Phosphotyrosine
Immunomodulation
Autoimmune Experimental Encephalomyelitis
Helianthus
Delayed Hypersensitivity
Subcutaneous Injections
Interleukin-2
Electrocardiography
Therapeutics
Calcium
Cell Line
Cardiotoxicity
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology

Cite this

Beeton, C., Pennington, M. W., Wulff, H., Singh, S., Nugent, D., Crossley, G., ... Chandy, K. G. (2005). Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Molecular Pharmacology, 67(4), 1369-1381. https://doi.org/10.1124/mol.104.008193

Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. / Beeton, Christine; Pennington, Michael W.; Wulff, Heike; Singh, Satendra; Nugent, Daniel; Crossley, George; Khaytin, Ilya; Calabresi, Peter; Chen, Chao Yin; Gutman, George A.; Chandy, K. George.

In: Molecular Pharmacology, Vol. 67, No. 4, 04.2005, p. 1369-1381.

Research output: Contribution to journalArticle

Beeton, C, Pennington, MW, Wulff, H, Singh, S, Nugent, D, Crossley, G, Khaytin, I, Calabresi, P, Chen, CY, Gutman, GA & Chandy, KG 2005, 'Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases', Molecular Pharmacology, vol. 67, no. 4, pp. 1369-1381. https://doi.org/10.1124/mol.104.008193
Beeton, Christine ; Pennington, Michael W. ; Wulff, Heike ; Singh, Satendra ; Nugent, Daniel ; Crossley, George ; Khaytin, Ilya ; Calabresi, Peter ; Chen, Chao Yin ; Gutman, George A. ; Chandy, K. George. / Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. In: Molecular Pharmacology. 2005 ; Vol. 67, No. 4. pp. 1369-1381.
@article{e40ac170cfb143b98991dc35f22c940d,
title = "Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases",
abstract = "The voltage-gated Kv1.3 K+ channel is a novel target for immunomodulation of autoreactive effector memory T (TEM) cells that play a major role in the pathogenesis of autoimmune diseases. We describe the characterization of the novel peptide ShK(L5) that contains L-phosphotyrosine linked via a nine-atom hydrophilic linker to the N terminus of the ShK peptide from the sea anemone Stichodactyla helianthus. ShK(L5) is a highly specific Kv1.3 blocker that exhibits 100-fold selectivity for Kv1.3 (Kd = 69 pM) over Kv1.1 and greater than 250-fold selectivity over all other channels tested. ShK(L5) suppresses the proliferation of human and rat TEM cells and inhibits interleukin-2 production at picomolar concentrations. Naive and central memory human T cells are initially 60-fold less sensitive than TEM cells to ShK(L5) and then become resistant to the peptide during activation by up-regulating the calcium-activated KCa3.1 channel. ShK(L5) does not exhibit in vitro cytotoxicity on mammalian cell lines and is negative in the Ames test. It is stable in plasma and when administered once daily by subcutaneous injection (10 μg/kg) attains {"}steady state{"} blood levels of ≃300 pM. This regimen does not cause cardiac toxicity assessed by continuous EKG monitoring and does not alter clinical chemistry and hematological parameters after 2-week therapy. ShK(L5) prevents and treats experimental autoimmune encephalomyelitis and suppresses delayed type hypersensitivity in rats. ShK(L5) might prove useful for therapy of autoimmune disorders.",
author = "Christine Beeton and Pennington, {Michael W.} and Heike Wulff and Satendra Singh and Daniel Nugent and George Crossley and Ilya Khaytin and Peter Calabresi and Chen, {Chao Yin} and Gutman, {George A.} and Chandy, {K. George}",
year = "2005",
month = "4",
doi = "10.1124/mol.104.008193",
language = "English (US)",
volume = "67",
pages = "1369--1381",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases

AU - Beeton, Christine

AU - Pennington, Michael W.

AU - Wulff, Heike

AU - Singh, Satendra

AU - Nugent, Daniel

AU - Crossley, George

AU - Khaytin, Ilya

AU - Calabresi, Peter

AU - Chen, Chao Yin

AU - Gutman, George A.

AU - Chandy, K. George

PY - 2005/4

Y1 - 2005/4

N2 - The voltage-gated Kv1.3 K+ channel is a novel target for immunomodulation of autoreactive effector memory T (TEM) cells that play a major role in the pathogenesis of autoimmune diseases. We describe the characterization of the novel peptide ShK(L5) that contains L-phosphotyrosine linked via a nine-atom hydrophilic linker to the N terminus of the ShK peptide from the sea anemone Stichodactyla helianthus. ShK(L5) is a highly specific Kv1.3 blocker that exhibits 100-fold selectivity for Kv1.3 (Kd = 69 pM) over Kv1.1 and greater than 250-fold selectivity over all other channels tested. ShK(L5) suppresses the proliferation of human and rat TEM cells and inhibits interleukin-2 production at picomolar concentrations. Naive and central memory human T cells are initially 60-fold less sensitive than TEM cells to ShK(L5) and then become resistant to the peptide during activation by up-regulating the calcium-activated KCa3.1 channel. ShK(L5) does not exhibit in vitro cytotoxicity on mammalian cell lines and is negative in the Ames test. It is stable in plasma and when administered once daily by subcutaneous injection (10 μg/kg) attains "steady state" blood levels of ≃300 pM. This regimen does not cause cardiac toxicity assessed by continuous EKG monitoring and does not alter clinical chemistry and hematological parameters after 2-week therapy. ShK(L5) prevents and treats experimental autoimmune encephalomyelitis and suppresses delayed type hypersensitivity in rats. ShK(L5) might prove useful for therapy of autoimmune disorders.

AB - The voltage-gated Kv1.3 K+ channel is a novel target for immunomodulation of autoreactive effector memory T (TEM) cells that play a major role in the pathogenesis of autoimmune diseases. We describe the characterization of the novel peptide ShK(L5) that contains L-phosphotyrosine linked via a nine-atom hydrophilic linker to the N terminus of the ShK peptide from the sea anemone Stichodactyla helianthus. ShK(L5) is a highly specific Kv1.3 blocker that exhibits 100-fold selectivity for Kv1.3 (Kd = 69 pM) over Kv1.1 and greater than 250-fold selectivity over all other channels tested. ShK(L5) suppresses the proliferation of human and rat TEM cells and inhibits interleukin-2 production at picomolar concentrations. Naive and central memory human T cells are initially 60-fold less sensitive than TEM cells to ShK(L5) and then become resistant to the peptide during activation by up-regulating the calcium-activated KCa3.1 channel. ShK(L5) does not exhibit in vitro cytotoxicity on mammalian cell lines and is negative in the Ames test. It is stable in plasma and when administered once daily by subcutaneous injection (10 μg/kg) attains "steady state" blood levels of ≃300 pM. This regimen does not cause cardiac toxicity assessed by continuous EKG monitoring and does not alter clinical chemistry and hematological parameters after 2-week therapy. ShK(L5) prevents and treats experimental autoimmune encephalomyelitis and suppresses delayed type hypersensitivity in rats. ShK(L5) might prove useful for therapy of autoimmune disorders.

UR - http://www.scopus.com/inward/record.url?scp=20144366005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144366005&partnerID=8YFLogxK

U2 - 10.1124/mol.104.008193

DO - 10.1124/mol.104.008193

M3 - Article

VL - 67

SP - 1369

EP - 1381

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -